Correlation between SV2A expression in tumour tissue and efficacy of levetiracetam in glioma patients with epilepsy.

Correlation between SV2A expression in tumour tissue and efficacy of levetiracetam in glioma patients with epilepsy. - SV2A expression and levetiracetam response in glioma patients.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON30525

Enrollment

Registered

2007-03-05

Start date

2007-04-01

Completion date

Unknown

Last updated

2024-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

epilepsy seizures

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: We will include adult (> 18 years) glioma patients who suffered from partial seizures, with or without secondary generalisation, preoperatively. Patients must have undergone surgery for their newly-diagnosed or recurrent glioma not more than 42 days previously and be treated with levetiracetam monotherapy at the time of inclusion.

Exclusion criteria

Exclusion criteria: Patients who do not have a basic proficiency of the Dutch language, or are unable to communicate adequately (e.g. due to dysphasia) will be excluded.

Design outcomes

Primary

Measure	Time frame
The primary study parameter is the total number of seizures during the study period, which is 6 months for every indivicual patient.	—

Secondary

Measure	Time frame
The secondary study parameters will be time to drug withdrawal due to inadequate seizure control (if applicable). Other study parameters will be change in cognitive function, quality of life, and brain activity as measured by MEG at the end of the study, compared with baseline.	—

Countries

Netherlands

Outcome results